Jacobs Levy Equity Management, Inc Sage Therapeutics, Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $24.2 Billion
- Q2 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 581,753 shares of SAGE stock, worth $5.05 Million. This represents 0.02% of its overall portfolio holdings.
Number of Shares
581,753
Previous 706,390
17.64%
Holding current value
$5.05 Million
Previous $5.62 Million
5.52%
% of portfolio
0.02%
Previous 0.02%
Shares
21 transactions
Others Institutions Holding SAGE
# of Institutions
77Shares Held
17.5MCall Options Held
282KPut Options Held
320K-
Black Rock Inc. New York, NY5.22MShares$45.3 Million0.0% of portfolio
-
Pictet Asset Management Sa Geneva 73, V8599KShares$5.2 Million0.03% of portfolio
-
Nuveen Asset Management, LLC Chicago, IL143KShares$1.24 Million0.0% of portfolio
-
Credit Suisse Ag Zurich, V8103KShares$897,5640.0% of portfolio
-
Equitec Proprietary Markets, LLC63.9KShares$554,6520.57% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $516M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...